- Home
- PALI vs LRMR Comparison
PALI vs LRMR Comparison
Compare PALI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PALI | LRMR |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.8M | 316.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PALI | LRMR |
|---|---|---|
| Price | $2.49 | $3.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $17.67 | $16.71 |
| AVG Volume (30 Days) | ★ 5.8M | 1.1M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $1.61 |
| 52 Week High | $2.64 | $5.37 |
Technical Indicators
Market Signals| Indicator | PALI | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 65.10 | 42.59 |
| Support Level | $2.24 | $3.43 |
| Resistance Level | $2.64 | $4.01 |
| Average True Range (ATR) | 0.18 | 0.24 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 89.39 | 18.52 |
Price Performance
Historical ComparisonAbout PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.